Skip to main content

Table 1 Multivariate analysis of tissue microarray cohort

From: STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma

Model

Variable

P-value

Hazard ratio

(95% CI)

A. Clinical pathology and STAG2

STAG2 (< 95%)

0.017

1.421 (1.064-1.898)

 

T stage (1/2)

0.729

1.066 (0.743-1.529)

 

N stage (N0)

0.196

0.826 (0.618-1.104)

 

Grade (1/2)

0.013

0.711 (0.544-0.93)

 

Sex (female)

0.865

1.023 (0.785-1.333)

 

Margin involvement (negative)

0.297

0.852 (0.63-1.151)

 

M stage (M0)

0.132

1.487 (0.887-2.492)

B. Clinical pathology and STAG2

STAG2 (< 95%)

0.017

1.415 (1.064-1.883)

 

T stage (1/2)

0.719

1.068 (0.746-1.531)

 

N stage (N0)

0.195

0.825 (0.618-1.103)

 

Grade (1/2)

0.013

0.713 (0.546-0.931)

 

Margin involvement (negative)

0.3

0.853 (0.631-1.152)

 

M stage (M0)

0.126

1.494 (0.894-2.497)

C. Clinical pathology and STAG2

STAG2 (< 95%)

0.016

1.42 (1.068-1.888)

 

N stage (N0)

0.198

0.827 (0.619-1.105)

 

Grade (1/2)

0.014

0.717 (0.55-0.934)

 

Margin involvement (negative)

0.321

0.861 (0.64-1.158)

 

M stage (M0)

0.131

1.484 (0.889-2.478)

D. Clinical pathology and STAG2

STAG2 (< 95%)

0.014

1.428 (1.074-1.898)

 

N stage (N0)

0.185

0.822 (0.616-1.098)

 

Grade (1/2)

0.011

0.709 (0.545-0.924)

 

M stage (M0)

0.086

1.556 (0.94-2.574)

E. Clinical pathology and STAG2 (final model)

STAG2 (< 95%)

0.021

1.394 (1.051-1.849)

 

Grade (1/2)

0.007

0.697 (0.536-0.906)

 

M stage (M0)

0.061

1.615 (0.979-2.665)

  1. CI, confidence interval.